ResearcherUniversidade do PortoActive in the last 2 years

Sofia Martins Sousa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3886-3923; OpenAlex author ID A5100732206. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper

Papers 1

Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-024-04712-1 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Cristina P. R. Xavier · 1 shared paper, 2024 · strength 0.22
- Paper Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. DOI 10.1007/s00280-024-04712-1 ↗
M. Helena Vasconcelos · 1 shared paper, 2024 · strength 0.22
- Paper Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. DOI 10.1007/s00280-024-04712-1 ↗
Luca Morelli · 1 shared paper, 2024 · strength 0.22
- Paper Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. DOI 10.1007/s00280-024-04712-1 ↗
Amir Avan · 1 shared paper, 2024 · strength 0.22
- Paper Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. DOI 10.1007/s00280-024-04712-1 ↗
Elisa Giovannetti · 1 shared paper, 2024 · strength 0.22
- Paper Darifenacin: a promising chitinase 3-like 1 inhibitor to tackle drug resistance in pancreatic ductal adenocarcinoma. DOI 10.1007/s00280-024-04712-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.